David A. Siegel Aldeyra Therapeutics, Inc. Transaction History

Two Sigma Advisers, LP

$46.1 Billion
Q2 2025

A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Aldeyra Therapeutics, Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 30,800 shares of ALDX stock, worth $165,088. This represents 0.0% of its overall portfolio holdings.

Number of Shares

30,800

Previous 33,100 6.95%

Holding current value

$165,088

Previous $190,000 38.42%

% of portfolio

0.0%

Previous 0.0%

23 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 14, 2025	SELL	$1.42 - $5.48 $3,266 - $12,604	-2,300 Reduced 6.95%	30,800 $117,000
Q1 2025 May 15, 2025	SELL	$4.7 - $6.98 $433,340 - $643,556	-92,200 Reduced 73.58%	33,100 $190,000
Q4 2024 Feb 14, 2025	SELL	$4.21 - $5.9 $353,640 - $495,600	-84,000 Reduced 40.13%	125,300 $625,000
Q3 2024 Nov 14, 2024	SELL	$3.19 - $6.32 $234,784 - $465,152	-73,600 Reduced 26.02%	209,300 $1.13 Million
Q2 2024 Aug 14, 2024	SELL	$3.25 - $4.72 $299,000 - $434,240	-92,000 Reduced 24.54%	282,900 $936,000
Q1 2024 May 15, 2024	BUY	$2.77 - $4.22 $65,095 - $99,170	23,500 Added 6.69%	374,900 $1.23 Million
Q4 2023 Feb 14, 2024	SELL	$1.47 - $6.06 $102,165 - $421,170	-69,500 Reduced 16.51%	351,400 $1.23 Million
Q3 2023 Nov 14, 2023	SELL	$6.11 - $8.16 $80,041 - $106,896	-13,100 Reduced 3.02%	420,900 $2.81 Million
Q2 2023 Aug 14, 2023	SELL	$7.11 - $11.89 $667,629 - $1.12 Million	-93,900 Reduced 17.79%	434,000 $3.64 Million
Q1 2023 May 15, 2023	SELL	$5.77 - $9.93 $358,894 - $617,646	-62,200 Reduced 10.54%	527,900 $5.24 Million
Q4 2022 Feb 14, 2023	SELL	$5.08 - $7.09 $1.56 Million - $2.18 Million	-307,500 Reduced 34.26%	590,100 $4.11 Million
Q3 2022 Nov 14, 2022	BUY	$3.8 - $7.74 $40,280 - $82,044	10,600 Added 1.2%	897,600 $4.79 Million
Q2 2022 Aug 15, 2022	BUY	$2.43 - $4.85 $921,699 - $1.84 Million	379,300 Added 74.71%	887,000 $3.54 Million
Q1 2022 May 16, 2022	SELL	$3.25 - $5.17 $589,875 - $938,355	-181,500 Reduced 26.33%	507,700 $2.26 Million
Q4 2021 Feb 14, 2022	SELL	$3.5 - $9.63 $347,200 - $955,296	-99,200 Reduced 12.58%	689,200 $2.76 Million
Q3 2021 Nov 15, 2021	SELL	$7.94 - $11.31 $1.8 Million - $2.57 Million	-227,100 Reduced 22.36%	788,400 $6.92 Million
Q2 2021 Aug 16, 2021	BUY	$10.44 - $14.85 $1.88 Million - $2.67 Million	180,100 Added 21.56%	1,015,500 $11.5 Million
Q1 2021 May 17, 2021	BUY	$6.53 - $14.42 $1.06 Million - $2.34 Million	162,100 Added 24.08%	835,400 $9.93 Million
Q4 2020 Feb 16, 2021	BUY	$6.31 - $8.13 $458,737 - $591,051	72,700 Added 12.1%	673,300 $4.62 Million
Q3 2020 Nov 16, 2020	BUY	$4.0 - $7.53 $2.09 Million - $3.94 Million	523,600 Added 680.0%	600,600 $4.45 Million
Q2 2020 Aug 14, 2020	BUY	$1.97 - $5.05 $84,119 - $215,635	42,700 Added 124.49%	77,000 $321,000
Q1 2020 May 15, 2020	BUY	$1.62 - $6.4 $39,204 - $154,880	24,200 Added 239.6%	34,300 $85,000
Q4 2019 Feb 14, 2020	BUY	$4.73 - $7.98 $47,773 - $80,598	10,100 New	10,100 $59,000

Others Institutions Holding ALDX

# of Institutions

136

Shares Held

34.9M

Call Options Held

263K

Put Options Held

51.6K

View Full List

About Aldeyra Therapeutics, Inc.

Ticker ALDX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 58,323,100
Market Cap $313M
Description
Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated ocular and systemic diseases. The company's lead product candidate is reproxalap, a reactive aldehyde species (RASP)modulator, which is in Phase III clinical trial for the treatment of dry eye diseases and allergic conjunctivitis. It al...

More about ALDX

Track David A. Siegel's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.

Account